Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bayer Monsan to asks...

    Bayer Monsan to asks U.S. court to toss $289 mln glyphosate verdict

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-09-20T13:47:13+05:30  |  Updated On 20 Sept 2018 1:47 PM IST


    US- Bayer AG unit Monsanto asked a California judge to throw out a $289 million jury verdict awarded to a man who alleged the company's glyphosate-based weed-killers, including Roundup, gave him cancer.


    The company said in motions filed in San Francisco's Superior Court of California that the jury's decision was insufficiently supported by the evidence presented at trial by school groundskeeper Dewayne Johnson.

    Johnson's case, filed in 2016, was fast-tracked for trial due to the severity of his non-Hodgkin's lymphoma, a cancer of the lymph system, that he alleged was caused by years of exposure to Roundup and Ranger Pro, another Monsanto herbicide that contains glyphosate.

    Monsanto asked Superior Court Judge Suzanne Bolanos, who oversaw the trial, to set aside the verdict or, in the alternative, reduce the award or grant a new trial. A hearing on the motions is set for Oct. 10.

    The company, which denies the allegations, has previously said it would appeal the verdict if necessary.

    Johnson's case was the first to go to trial over allegations that glyphosate causes cancer. Monsanto is facing some 8,000 similar lawsuits across the United States.

    Shares in Bayer, which bought Monsanto this year for $63 billion, slid following the Aug. 10 jury decision and the stock was still trading some 20 percent below its pre-verdict value of 73.30 euros ($85.45) on Tuesday.

    "The jury's decision is wholly at odds with over 40 years of real-world use, an extensive body of scientific data and analysis ... which support the conclusion that glyphosate-based herbicides are safe for use and do not cause cancer in humans," Bayer said in a statement.

    Bayer said Johnson failed to prove glyphosate caused his cancer and the scientific evidence he presented at trial "fell well below the causation standard required under California law."

    The U.S. Environmental Protection Agency in September 2017 concluded a decades-long assessment of glyphosate risks and found the chemical is not a likely carcinogen to humans. However, the cancer unit of the World Health Organization in 2015 classified glyphosate as "probably carcinogenic to humans."

    The jury found Monsanto failed to warn Johnson and other consumers of the cancer risks posed by its weed-killers. It awarded $39 million in compensatory and $250 million in punitive damages.

    The company in its motion for a new trial also said statements by lawyers for Johnson inflamed and inappropriately influenced the jurors. Some legal experts have said Monsanto faces long odds on appeal on those grounds.





    Californiacancer of lymph systemcarcinogenDewayne Johnsonglyphosatenon-Hodgkin's lymphomaRoundup and Ranger ProU.S. Environmental ProtectionWEED KILLERWorld Health Organization
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok